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Abstract
Although ovarian cancer is often initially chemotherapy-sensitive, the vast majority of tumors eventually relapse and
patients die of increasingly aggressive disease. Cancer stem cells are believed to have properties that allow them to survive
therapy and may drive recurrent tumor growth. Cancer stem cells or cancer-initiating cells are a rare cell population and
difficult to isolate experimentally. Genes that are expressed by stem cells may characterize a subset of less differentiated
tumors and aid in prognostic classification of ovarian cancer. The purpose of this study was the genomic identification and
characterization of a subtype of ovarian cancer that has stem cell-like gene expression. Using human and mouse gene
signatures of embryonic, adult, or cancer stem cells, we performed an unsupervised bipartition class discovery on
expression profiles from 145 serous ovarian tumors to identify a stem-like and more differentiated subgroup. Subtypes were
reproducible and were further characterized in four independent, heterogeneous ovarian cancer datasets. We identified
a stem-like subtype characterized by a 51-gene signature, which is significantly enriched in tumors with properties of Type II
ovarian cancer; high grade, serous tumors, and poor survival. Conversely, the differentiated tumors share properties with
Type I, including lower grade and mixed histological subtypes. The stem cell-like signature was prognostic within high-stage
serous ovarian cancer, classifying a small subset of high-stage tumors with better prognosis, in the differentiated subtype. In
multivariate models that adjusted for common clinical factors (including grade, stage, age), the subtype classification was
still a significant predictor of relapse. The prognostic stem-like gene signature yields new insights into prognostic
differences in ovarian cancer, provides a genomic context for defining Type I/II subtypes, and potential gene targets which
following further validation may be valuable in the clinical management or treatment of ovarian cancer.
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Introduction
Ovarian cancer is the fifth most common cause of cancer deaths
among women and is the leading cause of death from
gynecological neoplastic disease [1]. The vast majority of initially
responsive ovarian cancers eventually relapse [2], and this may be
explained by a sub-population of stem cell-like chemotherapy-
resistant tumors cells [3–5].
In breast cancer, there are widely-accepted molecular subtypes.
Approximately 15% of breast cancers are estrogen receptor (ER)-
negative, high-grade and often basal-like breast cancer that are
enriched in cells expressing putative stem cell markers CD44
+/
CD24
2 [6] and over-expresses genes associated with embryonic
stem cell gene signatures [7]. This ‘‘stemness’’ may be explained,
in part, by the observation that BRCA1, which is reported to
regulate mammary stem cell fate [8], is often mutated in basal-like
tumors [9].
In contrast, ovarian cancer has no consensus molecular subtype
classification. Tothill et al. used k-means clustering of microarray
data and described six molecular subtypes of serous and
endometrioid ovarian cancer [10]. The Cancer Genome Atlas
(TCGA) consortium identified four molecular subtypes of high
grade serous ovarian cancers [11]. However, others have proposed
pathology-site of origin based subtyping of ovarian cancer into
Type I tumors, which are low-grade and histologically heteroge-
neous, and Type II tumors, which are high-grade and mostly
serous [12,13]. Type II is believed to arise largely in the fallopian
tube epithelium while Type I’s site of origin is thought to be the
ovary, although the cell of origin remains unclear [12,13]. No
Type I/II molecular signature exists, and classifying tumors as
Type I or Type II based on clincopathologic analysis is generally
but not always straightforward [14].
Here we report the identification of ovarian cancer subtypes
based on the expression of genes associated with stem cell
signatures. Using a computational approach, we demonstrate the
PLOS ONE | www.plosone.org 1 March 2013 | Volume 8 | Issue 3 | e57799presence of a poor prognosis, stem cell-like subtype in ovarian
cancer that aligned closely with the cell of origin classification and
provides the first genomic definition of Type I/II ovarian cancer.
This gene expression profile does not demonstrate the existence of
a subpopulation of cancer stem cells in these tumors. Instead it
discovers common molecular pathways expressed by these cancers
and stem cells. Tumors displaying expression of stem-like genes
may have a less differentiated phenotype. Discovery of this stem
cell subtype provides us a more complete understanding of ovarian
cancer’s molecular diversity and opens up the potential for new
and more directed approaches to treating and managing the
disease.
Methods
Data
Stem-like cluster discovery was applied to ovarian cancer gene
expression data published by Tothill et al. [10], as part of the
Australian Ovarian Cancer Study (AOCS) data, and which were
downloaded from Gene Expression Omnibus (GEO) [15]
(GSE9891). AOCS samples (n=206), were obtained from the
Royal Brisbane Hospital (n=22), Westmead Hospital (n=54),
and Netherlands Cancer Institute (NKI-AVL; n=3) [10], and
gene expression was assayed on Affymetrix GeneChip U133 plus
2.0 arrays [10]. Raw data were normalized using RMA [16] with
custom cell description files (CDFs) based on Ensembl gene
mapping (version 12) as provided by the Microarray Lab at the
University of Michigan [17]. Custom CDFs were used because
updated probe set definitions provide better precision and
accuracy compared to Affymetrix probe set definitions [18].
The four validation ovarian cancer gene expression datasets
used in this analysis were from Dressman et al. [19]; Wu et al.
(GSE6008) [20]; Tone et al. (GSE10961) [21]; and Crijns et al.
[22]. The three validation breast cancer datasets were from Miller
et al. (GSE3494) [23]; Desmedt et al. (GSE7390) [24]; and
a merged dataset combining GSE2034 [25] and GSE5327 [26],
which we called ‘‘Veridex.’’ All datasets were downloaded from
GEO, except the Crijns dataset, which was received from the
authors in normalized form as described in their paper [22], and
the Dressman dataset was downloaded from the authors’ website
[19]. TCGA ovarian cancer microarray dataset (n=518) was
downloaded from the TCGA data portal [11]. All datasets other
than the Crijns, Wu, and Tone datasets were RMA-normalized
with custom Ensembl CDF’s [17].
RMA-normalization was used in most datasets because of its
highly reproducible results and correlation with RT-PCR data
[27]. However, due to the inclusions of normal fallopian tube in
the Tone dataset and normal ovarian surface epithelium samples
in the Wu dataset, these datasets were normalized using the
Invariant Set normalization method [28] to avoid the assumption
within RMA of equivalent gene expression distribution. All
validation data had been collected on Affymetrix GeneChip
U133a arrays, except for the Tone and Crijns datasets, which had
been collected on Affy U133 Plus 2.0 chips and Operon human v3
,35 K 70-mer two-color oligonucleotide microarrays, respective-
ly.
In the Desmedt and Veridex breast cancer datasets, we
predicted molecular subtypes as described by Desmedt et al.
(2008) [29]. Specifically, subtypes based on gene markers ESR1,
ERBB2, and AURKA were generated using the subtype.cluster
function with model scmgene in Bioconductor package genefu. This
entailed using mixture modeling to group patients into HER2+,
ER2/HER2- (basal-like), or ER+/HER2- (luminal) [29]. While
triple-negative breast cancer is not equivalent to basal-like breast
cancer [30–32], most triple-negative breast cancer classify to the
basal-like molecular subtype [32] leading us to regard prediction of
ER2/HER2- an approximation of ‘‘basal-like’’.
Statistical Analysis
Statistical analyses, unless otherwise described, were performed
using all available data and standard functions in R version 2.10.1.
The ISIS algorithm [33] was applied to the AOCS dataset to
generate unsupervised candidate bipartitions of the patients. For
each candidate bipartition, ISIS calculates a diagonal linear
discriminant (DLD) score with the most significant genes
supporting the bipartition. Default parameters of the R imple-
mentation of ISIS were used, except that the number of genes used
for scoring (‘‘p’’) was 100, a level which has been previously used
[34]. We also took advantage of another paramater (‘‘p.offs’’) by
ignoring the top 5 most related genes in order to reduce the effects
of high leverage genes on scoring, resulting in a 95-gene signature
used for scoring each bipartition.
To diminish confounding effects from differential stroma and
non-tumor cells in different arrayed sites (e.g. peritoneal or ovary)
(unpublished data), only AOCS arrays of ovarian mRNA from
malignant, serous, and primary site ovarian tumors from patients
that did not receive neoadjuvant therapy were included, reducing
the dataset from 285 to 145 patients. Analyses of the AOCS
dataset were performed on this subset unless we specify the
‘‘entire’’ AOCS dataset (n=285) or ‘‘remaining’’ AOCS data
(n=140), which were tumors not used for ISIS class discovery.
Genes used for subtype cluster discovery were limited to 83
mouse and human gene signatures of adult, cancer, or embryonic
stem cells obtained from GeneSigDB [35] that had at least 5 and
at most 1,000 genes. For each gene signature, we retrieved the
article describing the gene signature to confirm its description and
association with adult, cancer, or embryonic stem cells. Stem-like
gene signatures frequently contain proliferation genes [7]. To
avoid dividing patients based on proliferation, we also removed
genes (n=580, Table S1 in Methods S1) associated with
proliferation (see Methods S1), similar to analyses by Ben-Porath
we al. [7].
The resulting matrix of 2,632 stem-like genes was subject to
ISIS bipartition discovery. The highest scoring bipartition that was
significantly (p,0.05) associated with grade and disease-free
survival was selected for further investigation. These criteria were
based on the finding that the stem cell-like sub-population of
breast cancer tumors discovered by Ben-Porath et al. was
characterized by high grade and poor prognosis [7]. The
association with prognosis was secondary since the Ben-Porath
et al. analysis primarily described association between stem cell-
like gene expression and higher grade [7]. We selected the
bipartition that most closely satisfied the criteria and called this
bipartition the ‘‘stemness bipartition’’. Leave-one-out cross-
validation was used to refine the gene list defining the stemness
bipartition, and the genes which were in each 95-gene list in all
145 folds formed an ovarian cancer ‘‘51-gene stemness signature’’
(Table S2 in Methods S1).
Gene-Set-Enrichment Analysis (GSEA) with nonparametric
inference for linear models as implemented in gsealmPerm in the
package gsealm in Bioconductor [36] was performed with curated
gene sets (C2) and Gene Ontology (GO) gene sets (C5) from the
gene set database MSigDB version 3.0 [37]. GSEA was also
performed using the 13 stem cell gene sets of Ben-Porath et al.:
two describing embryonic stem cells; four activated by Nanog,
Oct4, and/or Sox2; four bound by the Polycomb repressive
complex 2 PRC2; and two activated by c-Myc [7].
Stem-Like Subtype of Ovarian Cancer
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To confirm the presence of the stem-like subtype in ovarian
cancer, the stem-like subtype classification was applied to multiple
independent microarray datasets. In order to predict the class of
new tumors, we first needed generate a ‘‘stemness molecular
classifier,’’ a model of gene weight which discriminated the stem-
like and differentiated tumors. Diagonal linear discriminant (DLD)
analysis [38] was used to train this gene classifier using expression
profiles of the 51 genes in the AOCS dataset (Table S2 in Methods
S1). To predict the subtype of new tumors, expression profiles
were projected as supplementary points onto the DLD axis, and
the DLD score was the weighted sum of the expression of the
genes. As the DLD scores of new ovarian tumors projected on this
axis were bimodally distributed (Figure S1 in Methods S1),
Gaussian mixture modeling [39] was used to define the two
populations and assign new tumors to either the stem-like or
differentiated subtype. The DLD score is the linear combination of
weighted expression of many genes, and although we did not
investigate the effect of batch-specific technical variation [40] in
depth, we found it robust to mild noise from missing data and
outliers in the datasets tested. This stemness molecular classifier
was applied to each validation dataset.
The ovarian cancer datasets used for validation are phenotyp-
ically and clinically heterogeneous, and contain different histolog-
ical subtypes, grades, prognoses, treatments and follow-up
protocols. Unless stated we did not control for phenotype
variation; instead we exploited the heterogeneity in datasets, in
particular histology and grade, to explore how the bipartition
associated with phenotypes beyond those represented in the
AOCS dataset and to determine the extent to which the stemness
molecular classifier could be generalized.
Results
Discovery of a Stem Cell-like Subtype in Ovarian Cancer
To explore whether ovarian cancer has a stem-like component,
we tested whether genes reported to be expressed by stem cells are
also expressed in a subset of ovarian tumors. To do this, we
extracted the union of all adult, cancer, or embryonic stem (ES)
cell gene expression signatures in GeneSigDB [35] as described in
Methods S1 to generate a list of 2,632 stem-like genes (Table S3 in
Methods S1).
We then took the AOCS ovarian cancer gene expression data
(n=145 patients) and considered only the 2,632 genes reported to
be expressed in stem cells. To this, we applied ISIS [33], an
unsupervised bipartition clustering algorithm that randomly
partitions samples into two subsets and selects the genes that most
significantly associate with the partition. ISIS identified twenty-
eight separate distinct, statistically significant patient bipartitions of
the data, and each of which was further tested for association with
grade and disease-free survival.
The top scoring bipartition, hereafter referred to as the ovarian
cancer stemness bipartition differentiated two distinct subgroups of
ovarian cancer patients: a set of 121 patients with worse disease
free (p=0.0541), overall survival (p=0.102), and higher grade
(p=0.00326) that was interpreted as more ‘‘stem cell-like’’ as these
tumors over-expressed a number of genes known to be associated
with stemness, and a smaller group of 24 patients with better
survival and lower grade that we refer to as the ‘‘differentiated’’
subgroup (Figure 1).
Leave-one-patient-out cross-validation was performed to extract
the most robust gene signature of this bipartition, resulting in a 51-
gene stemness signature (Table S2 in Methods S1). Although the
bipartition’s association with overall survival showed a trend and
did not reach conventional statistical significance, the signature
was significantly prognostic in subsequent analyses when the
sample size was larger (see below).
To provide further support for the phenotypes revealed by the
bipartition, we tested if gene targets known to be expressed in stem
cells were differentially regulated between the stem-like and
differentiated subtypes using gene set enrichment analysis (GSEA).
Thirteen lists of genes (Table S4 in Methods S1) which have been
previously used to characterize stem cells [7] but were not among
the initial 83 signatures used to discover the stem-like ovarian
subtype were examined. Activation targets of Nanog, Oct4, Sox2
and c-Myc, which are up-regulated in stem cells, were also up-
regulated in the stem-like subtype, and eight of nine of these gene
lists were significantly (p,0.05) different across the subtypes
(Table 1). Four sets of Polycomb-regulated genes, which charac-
terize more differentiated cells, were up-regulated in the differen-
tiated subtype when compared to the stem-like subtype and were
close to significance (p,0.10). Since some of these gene sets are
reported to be dependent on proliferation genes [7], we also
performed a modified gene set analysis with proliferation genes
excluded as previously described [7]. Even with this modification,
the stem-like subtype was enriched in gene expression of ES [41]
(p,0.0001), Nanog [42] (p,0.05), and c-Myc [43] (p,0.05)
targets. High expression of the same ES gene set is reported in
high-grade, estrogen receptor (ER)-negative breast tumors [7].
Identification of Functional Links to Basal-like Breast
Cancer
To further characterize tumors in the stem-like subtype, we
performed GSEA using all of the gene sets in MSigDB [37] to
identify which gene sets were enriched in genes differentially
expressed between tumors in the stem-like and differentiated
subtypes (again, these sets did not include the gene sets initially
utilized to discover the bipartition). Genes over-expressed by stem-
like tumors were especially enriched (p,0.0001) for gene sets
describing poor prognosis and undifferentiated cancers; high-
grade, invasive ovarian cancer; Myc targets; and embryonic stem
cells, BRCA1 mutation, estrogen receptor (ER)-negative status,
and the basal-like subtype in breast cancer (Table S5). In contrast,
gene sets strongly enriched in the differentiated subtype included
those related to cellular projections (Table S6), ER-positive breast
cancer, and low malignant potential (LMP) and low-grade ovarian
cancer (Table S5 in Methods S1).
Both high-grade, serous ovarian and basal-like breast cancer are
seen in women with mutant BRCA1 [9,44]. To investigate the
GSEA prediction that the stem-like serous ovarian cancer
molecular subtype is enriched for genes also expressed in high
grade basal-like breast cancer, we applied diagonal linear
discriminant analysis [38] to the AOCS ovarian cancer data to
train a stemness molecular classifier and predicted the ‘‘stem-like’’
or ‘‘differentiated’’ classification of tumors in two published breast
gene expression datasets (Desmedt [24] and Veridex [25,26]
datasets). The gene list we applied to the breast cancer datasets
was not optimized for breast cancer, and the DLD scores did not
exhibit bimodal distributions. However to maintain consistency
with the methodology applied to ovarian cancer data, we used the
same Gaussian mixture modeling approach to dichotomize the
DLD scores of breast cancers defining them as stem-like or
differentiated. The resulting stemness classification of breast
tumors confirmed the gene set analysis predictions; breast tumors
assigned to the stem-like subtype were significantly enriched in
basal-like molecular subtype and high-grade (logistic regression
likelihood ratio test p=1.42610
29 and p=0.00964, Desmedt and
Veridex datasets respectively – Table 2) breast cancer.
Stem-Like Subtype of Ovarian Cancer
PLOS ONE | www.plosone.org 3 March 2013 | Volume 8 | Issue 3 | e57799Figure 1. Heatmap of gene expression and Kaplan-Meier survival curves for the stemness bipartition. (A) A heatmap of gene expression
profiles of the 24 differentiated (green) and 121 stem-like (blue) tumors from the AOCS dataset [10]. The tumors are ordered by increasing stemness
molecular subtype score, and the 51 classifier genes are ordered from top to bottom by increasing over-expression in the stem-like subtype
according to a pooled t-test. The Kaplan-Meier curves are with respect to (B) disease-free survival and (C) overall survival and are not significant at
p,0.05, but this is possibly due to the small size of the differentiated subtype.
doi:10.1371/journal.pone.0057799.g001
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Independent Datasets
To validate our ovarian stem-like and differentiated molecular
subtypes, we applied the stemness DLD molecular classifier to
three independent ovarian cancer microarray datasets and the
‘‘remaining AOCS data’’ (n=140) not used in the initial
bipartition discovery. Two datasets, Crijns et al. [22] and Dress-
man et al. [19], consisted of high-stage, serous tumors, while the
other two, the Wu et al. dataset [20] and the remaining AOCS
data [10] were histologically heterogeneous.
First, we confirmed the association between grade and the stem-
like molecular subtype. In these independent data, stem-like
tumors had higher grade in the Wu (n=103, logistic regression
p=1.63610
25), remaining AOCS (n=140, p=1.16610
27), and
Dressman (n=118, p=0.073) datasets.
Next we explored which histological subtypes of ovarian cancer
were classified as stem-like. Serous is the most common
histological form of epithelial ovarian tumor, but epithelial ovarian
cancer is a heterogeneous disease with mixed malignancy
potentials and histological subtypes, including endometrioid, clear
cell, and mucinous [12,13]. Despite initial classification being
performed only on malignant, serous tumors, the stemness
molecular classifier discriminated between different histological
subtypes. In the Wu dataset [20], most serous tumors (29/41) were
‘‘stem-like’’, but most endometrioid (22/37), almost all clear cell
(7/8), and all mucinous (13/13) tumors, as well as all four (4/4)
‘‘normal’’ ovarian surface epithelium samples were ‘‘differentiat-
ed.’’
To further evaluate association with histological subtype, we
examined the entire AOCS dataset (n=285). This larger dataset
was comprised of the serous AOCS discovery dataset (n=145) and
the remaining AOCS data (n=140), which included LMP serous
tumors and malignant endometrioid and serous tumors arrayed
from sites other than the ovary. We observed that the differen-
tiated subtype was significantly enriched in endometrioid tumors
(9/20, Fisher’s test p,0.05 after FWER correction [45]). Of note,
the stemness DLD scores were significantly lower in the LMP
serous tumors (Wilcoxon rank-sum test p-value=1.09610
24) than
in the malignant, differentiated tumors, and almost all (17/18)
LMP tumors were classified as differentiated. Additionally, within
the stem-like subtype the DLD score was significantly associated
with higher grade (p=0.00159), though it was not correlated
(p.0.05 after FWER correction) with stage, overall survival, or
disease-free survival, suggesting that further investigation into the
clinical value of the continuous DLD score within subtypes is
warranted.
The stem-like subtype classification was not equivalent to the
classification recently proposed by Tothill et al. in which serous
and endometrioid tumors are identified as one of six molecular
subtypes, C1–C6 [10]. The stem-like tumors (n=233) were not
classified into a single molecular subtype but instead were mostly
distributed among poor prognosis subtypes C1 (n=80), C2
(n=48), C4 (n=39), C5 (n=29) and Not Classified (n=30). A
considerable number of differentiated tumors were in good
prognosis molecular subtypes C3 (n=25) and C6 (n=4), and
the remaining 23 differentiated tumors were distributed among the
other subtypes (Table 3). So, while the bipartition roughly
separated better prognosis low-grade subtypes C3 and C6 from
the others and overlap with the molecular subtype classification
was significant, no combination of AOCS subtypes fully explained
the bipartition. However, it should be noted that the C1–C6
subtype classification was arrived at using k-means clustering [10],
a method that is not deterministic in the sense that re-running the
algorithm can produce different clusters, so the assignments by the
Table 1. The stem-like and differentiated subtypes are enriched in stem cell and differentiated gene sets respectively.
Gene Set Enrichment P-value Adjusted P-value*
Embryonic stem cell genes ES exp1 Stem-like 0.00002 0.00004
ES exp2 Stem-like 0.00031 0.01671
NOS targets Nanog targets Stem-like 0.00115 0.01573
Oct4 targets Stem-like 0.01509 0.07951
Sox2 targets Stem-like 0.02296 0.12607
NOS targets Stem-like 0.00969 0.10489
NOS TFs Stem-like 0.09596 0.13822
Myc targets Myc targets1 Stem-like 0.01144 0.03774
Myc targets2 Stem-like 0.01349 0.10387
Polycomb targets Suz12 targets Differentiated 0.05251 0.05508
Eed targets Differentiated 0.06293 0.05605
H3K27 bound Differentiated 0.05046 0.06329
PRC2 targets Differentiated 0.08553 0.09058
*Analysis was repeated after removing proliferation-related genes from the gene sets, as described by Ben-Porath et al. [7]. No multiple testing correction was
performed.
doi:10.1371/journal.pone.0057799.t001
Table 2. The stem-like subtype is significantly
overrepresented in basal-like breast cancer.
Desmedt*** Veridex***
Basal Non-basal Basal Non-basal
Stem-like 35 14 90 63
Differentiated 11 138 12 179
***Fisher’s exact test p=3.50610
218 and p=1.11610
227, Desmedt and Veridex
datasets respectively.
doi:10.1371/journal.pone.0057799.t002
Stem-Like Subtype of Ovarian Cancer
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the stem-like phenotype.
In the three independent validation datasets and the remaining
AOCS data, tumors with the stem-like subtype had worse
prognosis (Figure 2). The stem-like subtype had both significantly
worse overall survival (log-rank test p=4.41610
27) and disease-
free survival (p=0.00127) in the remaining AOCS dataset
(n=140) and worse overall survival in the Crijns (n=157,
p=0.021) and Dressman datasets (n=118, p=0.0354). Although
the Wu dataset [20] did not include survival information, the stem-
like subtype’s tumors had significantly higher stage (n=103,
p=1.03610
26), which suggests worse prognosis.
A finding of potential clinical importance is that the stemness
molecular classifier may also be prognostic within high-grade,
Table 3. Clinical characteristics of patients in stem-like and differentiated subtypes.
Dataset Differentiated Stem-like P-value
Wu et al Stage I 31 4 ***
(n=103) II 6 5
III 13 31
IV 4 5
Grade 1 18 1 ***
29 8
31 4 2 4
Histology Clear Cell 7 1 ***
Endometrioid 22 15
Mucinous 13 0
OSE 4 0
Serous 12 29
Entire AOCS Type LMP 17 1 ***
(n=285) Malignant 35 232 ***
Stage I 15 9
II 8 10
III 28 189
IV 1 21
Grade 1 14 5 ***
21 9 7 8
3 17 147
Histology Adenocarcinoma 0 1 *
Endometrioid 9 11
Serous 43 221
Primary site Fallopian tube 0 8 **
Ovary 52 191
Peritoneum 0 34
Arrayed Site Other 0 14 ***
Ovary 50 150
Peritoneum 2 69
Age Median age 56.3 59.3 *
Residual disease ,1 cm 43 118 **
.1c m 5 7 6
Molecular subtype C1 3 80 ***
C2 2 48
C3 25 3
C4 7 39
C5 7 29
C6 4 4
NC 4 30
**p-value ,0.01,
***p-value ,0.001. OSE Ovarian surface epithelium, NC not classified. In each dataset, p-values were corrected for family-wise error rate using Hommel’s method [46],
except for the test for association with the Tothill et al. molecular subtypes.
doi:10.1371/journal.pone.0057799.t003
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disease-free (p=0.0053) and overall survival (p=0.0299) in high-
grade, malignant tumors of the entire AOCS dataset. In
independent analysis of each histology, the stem-like subtype was
associated with poorer disease-free survival in high-grade serous
(p=0.0447), but was not a significant predictor in high-grade
endometrioid tumors (p=0.278). In the Crijns and Dressman
datasets, which were exclusively high-stage serous tumors, the
stemness molecular classifier identified a small subset of differen-
tiated subtype tumors with better overall survival (Figure 2).
Equally, across datasets the differentiated subtype included a small
number of high-grade tumors (grades 2 or 3) [14] with better
prognosis. Further analysis is needed to determine if this
classification is useful in identifying high-grade tumors more likely
to have a favorable outcome.
The stem-like subtype was associated with phenotypes often
predictive of poor outcome (Table 3), but the stem-like subtype’s
prognostic ability is not fully explained by these common clinical
variables. In the entire AOCS dataset the stem-like subtype was
a strong predictor of outcome (univariate analysis DFS
Figure 2. Validation of the stemness bipartition in independent ovarian cancer microarray datasets, as well as in the remaining
AOCS dataset. In the remaining AOCS dataset, the stem-like subtype has strongly worse (A) disease-free survival (p,0.001) and (B) overall survival
(p=0.00127). In the (C) Crijns and (D) Dressman datasets, the stem-like subtype has significantly worse overall survival (p=0.022 and p=0.035,
respectively).
doi:10.1371/journal.pone.0057799.g002
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26, OS p=0.00122), was associated with greater
patient age (p,0.05), and was strongly (p,0.001 after FWER
correction [46]) associated with high stage; peritoneal arrayed site,
a site to which high-grade ovarian cancer frequently spreads; and
greater residual disease after surgery.
Despite these associations, in multivariate analysis, the stemness
bipartition remained a strong predictor of worse disease-free
survival. The bipartition remained a significant predictor of
disease-free survival when adjusting for one (p,0.005) or two
variables among stage, grade, and residual disease (Table 4) or any
combination of two variables (p,0.05) in Table 3, with the
exception of adjusting for both stage and low malignancy potential
(p=0.0785). Notably, the stem-like subtype had significantly worse
disease-free survival (p=0.0143) in multivariate analysis adjusting
for grade, histological subtype, and low malignancy potential.
Even when adjusting for stage, low malignancy potential,
histological subtype, and grade, the stem-like subtype still had
a 54% increased odds of relapse, although this was not significant
(p=0.126).
Stem-like Tumors have Characteristics of Type II Ovarian
Cancer
A recent pathogenesis model of ovarian cancer divides tumors
into Type I, which is low-grade and histologically diverse, and
Type II, which is high-grade and mostly serous [12,13]. A gene
signature-based molecular classification for Type I/II ovarian
cancer has not yet been described, and Type I/II are distinguished
largely based on their morphological properties (Table 5). In
comparing our molecular subtypes to these morphological
classifications, we found stem-like tumors to possess characteristics
of Type II ovarian tumors and the differentiated tumors to be
similar to Type I (Table 5).
Both Type II and the stem-like subtype are associated with poor
prognosis, high-grade serous tumors (Table 5). Although formal
evaluation of the stem-like and differentiated subtypes’ prevalence
and lethality would require prospective random sampling of
ovarian carcinomas and subsequent classification, the stem-like
subtype properties would appear to be consistent with the reports
Type II’s relative prevalence and lethality (Table 5).
Mutations characteristic of Type II ovarian cancer are found in
the stem-like subtype. Type II tumors are thought to arise from
precursor lesions in fallopian tube epithelium and have ‘‘p53
signatures’’ that have strong p53 immunoreactivity and usually
p53 mutations [13]. It is reported that most Type II ovarian
tumors (.80%) have p53 mutation [12]. TCGA ovarian cancer
data consists of 489 high-grade serous ovarian adenocarcinomas
and almost all have TP53 mutation (96%) [11]. In our analysis
stemness molecular subtype scores of TCGA ovarian cancers
lacked bimodality and most tumors were classified into one
subtype which was more stem-like (data not shown). The mutation
status of almost all samples in other ovarian microarray datasets
are unknown but Wu et al. [20] reported p53 mutation status of
endometrioid tumors (n=37), and these endometrioid tumors with
p53 mutations were overrepresented in the stem-like subtype
(p=0.016). In addition, we observed that genes expressed by the
stem-like ovarian cancer subtype are enriched for two gene sets
that are over-expressed by p53-mutant breast cancers relative to
breast cancer without p53 mutation [47,48] (GSEA p-values
0.00008 and 0.00004, respectively in AOCS dataset–Table S7 in
Methods S1). To confirm this association, we applied the stemness
bipartition classification to a breast cancer dataset in which the
p53 status of tumors is known [23], and the stem-like subtype had
strong overlap with p53-mutant tumors (Fisher’s exact test
p=1.36610
212).
Differentiated Tumors have Characteristics of Type I
Ovarian Cancer
In contrast, ‘‘differentiated’’ tumors and Type I tumors describe
histologically diverse and mostly (although not exclusively) low-
grade and LMP tumors (Table 5). Type I tumors are characterized
by other mutations (including KRAS, BRAF, PTEN, and
PIK3CA and others shown in Table 5) [12], and we observed
Table 4. Multivariate Cox proportional hazards models of the stemness bipartition to predict relapse-free survival when adjusting
for two prognostic variables (A) residual disease and stage, (B) grade and stage or (C) grade and residual disease.
Variable Hazard ratio Lower limit (95% CI) Upper limit (95% CI) P-value
(A) Adjusting for residual disease and stage
Stem-like subtype 1.75 1.00 3.05 0.0498*
Residual disease 1.43 1.02 2.00 0.0374*
Stage
1 7.30 2.57 20.8 0.000195***
(B) Adjusting for grade and stage
Stem-like subtype 2.17 1.22 3.85 0.00818**
Grade
1 1.16 0.586 2.29 0.674
Stage
1 7.72 2.80 21.2 7.64610
25 ***
(C) Adjusting for grade and residual disease
Stem-like subtype 2.36 1.32 4.22 0.00370**
Grade
1 1.42 0.672 3.01 0.358
Residual disease 1.76 1.26 2.46 0.000872***
*p,0.05,
**p,0.01,
***p,0.001.
1In regression analyses, the ordinal variables stage and grade were broken into multiple components using default functions in R. However, only the linear components
(levels treated as a continuous variable) are displayed in the table because the other components were not significant. Grade was also coded as a quadratic component
(grade 2 vs. grades 1 and 3) and stage as both quadratic (stages 2 and 3 vs. stages 1 and 4) and cubic (stage 2. stage 4. stage 1. stage 3) components.
doi:10.1371/journal.pone.0057799.t004
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PTEN, or PIK3CA mutations were characterized as differentiat-
ed. Moreover, all 13 tumors in this dataset with b-catenin
accumulation were differentiated, which is consistent with
aberrations in Wnt signaling seen in low-grade endometrioid
tumors [12]. Thus, the subtype classification was consistent with
reported mutation status of Type I/II tumors.
Type I tumors purportedly arise from either ovarian surface
epithelium that undergoes metaplasia or epithelium of fallopian
tube, endometrium, or peritoneum that proliferates after being
trapped in ovarian cortical inclusion cysts [13] with the cell of
origin possibly being normal fallopian tube epithelium (FTE) that
sheds by endosalpingiosis [12,13]. We tested whether the
differentiated subtype’s gene expression patterns are similar to
that of normal FTE by applying our stemness classification to the
Tone et al. dataset [21] in which the authors compared expression
profiles of serous ovarian cancer and normal FTE from women
with and without BRCA1/2 mutation. Our stemness classification
assigned 13/13 ovarian cancer samples to the stem-like group and
24/24 FTE samples to the differentiated. Although all four normal
OSE samples in the Wu dataset [20] were also classified as
‘‘differentiated,’’ these results suggest substantial similarity in gene
expression profiles between FTE and the differentiated subtype.
Consistent with the hypothesis that Type I (but not Type II)
tumors are enriched for expression of genes associated with cilia
[12], the differentiated subtype of the AOCS dataset (n=145) was
enriched in gene sets associated with cilia, such as apical
projections gene sets (Table S6 in Methods S1) and FOXJ1,
which is required for ciliogenesis [49] and has been proposed as
a marker for ciliated fallopian tube cells [50]. FOXJ1 is not in the
51-gene stemness signature but was strongly up-regulated in the
differentiated subtype compared to the stem-like subtype (t-test
p=4.87610
27). These observations provide evidence for the
hypothesis that Type II/high-grade serous ovarian cancer arises
from non-ciliated epithelial cells [13].
Therefore, the Type I/II and stemness classifications are similar
in terms of grade, histological subtype, prevalence, and lethality, in
addition to cell of origin, presence of ciliated cells, and mutation
status (Table 5). From a gene expression point of view, Type II
ovarian tumors may be more stem-like in their gene expression. If
this molecular definition holds in further prospective studies, our
stem-like classification would represent a molecular classification
system that could establish the Type I/II system and provide
insight into possible mechanism and therapies for these subtypes.
Biological Basis of the Stem-like Gene Classifier
Of the 51 genes used for classification, 37 were present in all
four ovarian cancer datasets used for clinical validation (remaining
AOCS, Wu, Dressman, and Crijns), because the gene expression
profiling was performed on different technological platforms. Of
these, a subset of 12 were consistently over-expressed (p,0.05
after FDR correction) in either the stem-like or differentiated
subtypes across the four datasets and are thus most robustly
expressed. The six stem-like subtype genes were UVRAG,
CXCR4, RGS19, RAD51AP1, PSAT1, and CXCL10, and the
six differentiated subtype genes were FOXA2, EIF1, MTUS1,
DFNB31, TRAF3IP2, and SLC22A5. Despite enrichment in gene
expression of the targets of Nanog, Oct4, and Sox2 in the stem-like
subtype (Table 1), we did not find that that these genes were
differentially expressed between the stem-like and differentiated
subtypes.
Discussion
The cancer stem cell theory proposes that a subpopulation of
cells inherit or acquire stem-like properties that enable them to
survive therapy and drive recurrent tumor growth, but the
function and identification of such stem cells is controversial both
in normal and malignant ovarian and fallopian tube tissue [51–
53]. We have not demonstrated the existence of cancer stem cells
in ovarian cancer; instead our analysis identified a subtype of
ovarian cancer with stem-like gene expression which provides
a new molecular subtype classification of ovarian cancer,
a genomic context for further investigation of type I/II ovarian
cancers and insights into why ovarian cancer is so likely to be fatal
despite aggressive therapy.
Tumors identified as being of the stem-like subtype have higher
tumor grade and significantly worse prognosis, properties that
were reproducible in independent and heterogeneous ovarian
cancer microarray datasets; the associations between stem cell-like
gene expression and grade or survival have been observed before
but has not been explored in ovarian cancer [7,54]. In our
analysis, stemness was also a significant predictor of disease-free
survival in multivariate analyses that adjusted for prognostic
variables, such as grade and stage. Thus, this classification’s
Table 5. Shared characteristics of Types I and II ovarian cancer and the stem-like and differentiated subtypes [12].
Type I Type II Stemness bipartition
Presence of ciliated cells Possibly No Differentiated subtype is enriched in genes related to cilia and
more similar to normal fallopian tube.
Histological subtypes Serous, endometrioid, mucinous,
clear cell
Mostly serous Stem-like subtype overrepresented serous ovarian cancer while the
differentiated subtype had mixed histology (Table 3).
Mutations KRAS, BRAF PTEN, CTNNB1,
ERBB2, PIK3CA
Mostly p53 Stem-like subtype is enriched in p53-mutant tumors and p53
mutation-associated genes. Differentiated subtype is enriched in
other mutations.
Benign tumors Sometimes No Almost all 18 of the LMP tumors were classified as differentiated in
entire AOCS dataset.
Grade Low grade High grade Stem-like subtype has higher grade across datasets.
% epithelial ovarian
carcinomas
25% 75% Original stem-like subtype comprises 83% of the tumors and in
entire AOCS dataset, 77% of tumors.
% ovarian cancer deaths 10% 90% Stem-like consists of 91% of deaths in original bipartition and 94%
in entire AOCS dataset.
doi:10.1371/journal.pone.0057799.t005
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variables.
The classification is also valuable because of similarity to and
support for a subtype classification associated with distinct
pathogenesis pathways. Type I ovarian cancer, which includes
low-grade and histologically heterogeneous tumors that may arise
in the ovary, is similar to the differentiated subtype while Type II,
which includes high-grade and mostly serous tumors that arise in
the fallopian tube, is similar to the stem-like subtype [12,13]. This
is the first potential gene expression-based description of Type I
and II ovarian tumors (a distinction that up to now was mainly
morphologic), and thus it provides rationale for new biologic and
treatment hypotheses.
Our signature classified a low number of high-grade, serous
tumors, which would normally be classified as Type II, as Type I.
The identification of good prognosis, high-grade serous carcino-
mas may reflect novel biological insight or gene expression
patterns of tumors that were originally low-grade and became
high-grade [55]. Alternatively, these tumors may reflect initial
misclassification in tumor grade because such clinical pathological
classification of Type I and II tumors is mostly not always
straightforward [14].
The 51 classification genes we identified may provide insight
into pathogenesis of Type I and II ovarian cancer. FOXA2, which
is consistently up in the differentiated subtype, is an inhibitor of the
epithelial-mesenchymal transition associated with invasion and
metastasis [56,57]. On the other hand, CXCR4, which is
consistently highly expressed in the stem-like subtype, is implicated
in ovarian cancer metastasis [58], and is a potential therapeutic
target of drugs such as CXCR4 antagonists AMD3100 [58] and
CTCE-9908 [59]. Other genes including UVRAG and RA-
D51AP1 are implicated in DNA damage response, which has been
recently linked to cell differentiation status [60].
The stem-like subtype was enriched in stem cell-related gene
sets, including gene targets of stem cell markers Oct4 and Nanog,
which are reported to be associated with grade and stage in serous
ovarian cancer [61,62]. Although many common markers of stem
cells or EMT were not up-regulated in stem-like ovarian cancer,
expression of stem cell markers were also not observed in the stem
cell-like high-grade, ER-negative breast cancer [7]. This may be
because stem cell markers are up-regulated in a minority of cancer
stem cells which would not be reflected in gene expression
profiling of whole tumor. Kim et al. proposed that Myc activity
explains the apparent contradiction between the predictive power
of stem cell-related transcriptional programs and the absence of
canonical stem cell gene expression [61,62]. In our analysis, we
observed an enrichment of the Kim et al. Myc module in the
stem-like subtype, but without an over-expression of Myc (AOCS
dataset t-test p=0.445).
The stem-like subtype was predominant in high grade serous
ovarian and basal-like breast cancer supporting common bi-
ological connections between these cancers that also share BRCA1
dysfunction [9,44] and p53 mutation [63].Molecular similarities
between basal-like breast cancer and high-grade serous ovarian
cancer have been described in other studies, including the recent
study by the Cancer Genome Atlas Network [64]. Inactivation of
p53 in breast cancers has been shown to correlate with stem cell
transcriptional signatures [65] and the basal-like subtype [9] in
breast cancer. The guardian of the genome, p53 maintains DNA
integrity and DNA repair processes but also plays an important
role in stem cell and cell state reprogramming. While the majority
of ovarian cancer patients (, 80%) have tumors of the stem-like
subtype, the stem-like is observed in only 15% of breast cancers
which may partially explain the relatively poor prognosis in
ovarian cancer [1]. Our analysis provides additional support that
therapies effective in basal-like breast may also be may also be
effective in high grade serous ovarian cancer. Poly(ADP-ribose)
polymerase (PARP) inhibitors, which are especially effective in
cancer associated with BRCA1 or BRCA2 mutation [66], have
shown considerable promise in triple-negative breast cancer [67]
and may be valuable in treating high-grade serous Type II ovarian
cancer [68].
We present a prognostic stem-like subtype classification of
ovarian cancer which provides a genomic context for the Type I/
II classification. Though it does not explain all variation in
survival, in combination with other clinical indicators, it may have
the potential to explain prognosis with greater accuracy than
currently used clinical variables can alone. This classification
requires further experimental validation in a large cohort of
patients to characterize the properties of each molecular subtype,
their association with Types I and II ovarian cancer and
demonstrate possible clinical application. Our study provides
support for the recently described Type I/II model of ovarian
cancer and provides a molecular signature for stratification of
these subtypes.
Supporting Information
Methods S1 This file contains: Figure S1 Distributions of
stemness bipartition diagonal linear discriminant (DLD) scores in
each dataset. In the ovarian cancer datasets, the DLD scores were
all bimodal, and Gaussian mixture modeling [39] of the score was
used to classify the lower scoring group as differentiated and the
higher scoring group as stem-like. In the breast cancer datasets,
mixture modeling was still used to discover approximate stem-like
and differentiated classes, despite lack of clear bimodality. The
range of scores is inconsistent in different datasets, because genes
were often lost when crossing microarray platforms and potentially
because of batch effects across datasets. Table S1 Proliferation
genes (see Supplementary Methods) that were removed from the
set of 83 GeneSigDB [35] gene signatures that were used for class
discovery with ISIS [33]. After removing these genes, 2,632 genes
were still used for class discovery.Table S2 Genes used to generate
the stemness bipartition and their corresponding weights when
predicting the bipartition in other datasets, as well as pooled t-
statistics for differential expression between the stem-like and
differentiated subtypes. Negative weights correspond to the
differentiated subtype and positive weights correspond to the
stem-like subtype. Table S3. A list of the 83 gene signatures from
GeneSigDB [35] that are reported to be associated with stem cells.
Table S4 The 13 gene sets used by Ben-Porath et al. to
characterize classes of cancer as stem cell-like or differentiated.
Genes in these gene sets were limited to those that were in the
DNA microarray platform (Affy U133 Plus 2.0 platform) of the
AOCS data [10]. Table S5 Gene-Set-Enrichment p-values for
enrichment in stem-like and differentiated subtypes for all of the
curated gene sets on MSigDB v 3.0. No multiple testing correction
was used. Table S6 Gene-Set-Enrichment p-values for enrichment
in stem-like and differentiated subtypes for all of the Gene
Ontology gene sets on MSigDB v 3.0. No multiple testing
correction was used. Table S7 Genes over-expressed in breast
cancer cells containing wild type and mutant p53 from Figure 5 of
Troester et al. [47] and Table 1 of Takahashi et al. [48] and
whether they are over-expressed in the stem-like or differentiated
subtype. P-value is for over-expression in either the stem-like or
differentiated class and was calculated with the likelihood ratio test
for logistic regression. Only genes in the AOCS dataset were
considered. No multiple testing correction was performed. In the
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of mutant p53 genes in stem-like subtype was 0.00004 and p-value
for enrichment of WT p53 genes in differentiated subtype was
0.00005. These p-values were 0.00008 and 0.05144, respectively,
in the Takahashi et al. signature.
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